CoChat

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

Open access
de Moel, Emma C., Rozeman, Elisa A., Kapiteijn, Ellen H., Verdegaal, Els M.E., Grummels, Annette, Bakker, Jaap A., Huizinga, Tom W.J., Haanen, John B., Toes, René E.M., van der Woude, Diane · 2019 · Cancer Immunology Research

Published version of a preprint

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Abstract

Immune-checkpoint inhibitors (ICIs) activate the immune system to assault cancer cells in a manner that is not antigen specific. We hypothesized that tolerance may also be broken to autoantigens, resulting in autoantibody formation, which could be associated with immune-related adverse events (irAEs) and antitumor efficacy. Twenty-three common clinical autoantibodies in pre- and posttreatment sera from 133 ipilimumab-treated melanoma patients were determined, and their development linked to the occurrence of irAEs, best overall response, and survival. Autoantibodies developed in 19.2% (19/99) of patients who were autoantibody-negative pretreatment. A nonsignificant association was observed between development of any autoantibodies and any irAEs [OR, 2.92; 95% confidence interval (CI) 0.85-10.01]. Patients with antithyroid antibodies after ipilimumab had significantly more thyroid dysfunction under subsequent anti-PD-1 therapy: 7/11 (54.6%) patients with antithyroid antibodies after ipilimumab developed thyroid dysfunction under anti-PD1 versus 7/49 (14.3%) patients without antibodies (OR, 9.96; 95% CI, 1.94-51.1). Patients who developed autoantibodies showed a trend for better survival (HR for all-cause death: 0.66; 95% CI, 0.34-1.26) and therapy response (OR, 2.64; 95% CI, 0.85-8.16). We conclude that autoantibodies develop under ipilimumab treatment and could be a potential marker of ICI toxicity and efficacy.

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0245

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Cited by

See all 191

Metadata

Authors
de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D.
Affiliations
  • 1Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • The Netherlands Cancer Institute (NL)
  • Leiden University Medical Center (NL)
Venue
Cancer Immunology Research
Published
2019-01-01
Volume
7
Issue
1
Pages
6-11
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2901290947
Cited by
191
References
42
Citations by year
2026: 15 · 2025: 25 · 2024: 33 · 2023: 29 · 2022: 33 · 2021: 26 · 2020: 26 · 2019: 3
FWCI
5.16
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
Netherlands Organisation for Health Research and Development (91617100)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
autoantibodies, immune checkpoint inhibitors, ipilimumab, immune-related adverse events, melanoma, thyroid autoantibodies, thyroid dysfunction, anti-PD-1 therapy, self-tolerance, treatment response, survival
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Aged, Autoantibodies, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Thyroid Gland, Biomarkers, Treatment Outcome, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0245
The paper
de Moel, E. C., Rozeman, E. A., Kapiteijn, E. H., Verdegaal, E. M. E., Grummels, A., Bakker, J. A., Huizinga, T. W. J., Haanen, J. B., Toes, R. E. M., & van der Woude, D. (2019). Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0245

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.